APVO-425

N/A

Report date: 2026/03/19 17:23:59

Base Information

Drug NameAPVO-425

Drug Alias NameES-425APVO-425

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonistsT cell surface glycoprotein CD3 inhibitorsWnt signalling pathway modulators

TargetsT cell surface glycoprotein CD3Inactive tyrosine-protein kinase transmembrane receptor ROR1

Therapy Area/IndicationsTriple Negative Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesEmergent Biosolutions Inc Aptevo Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesEmergent Biosolutions Inc

Active IndicationsN/A

Inactive IndicationsTriple Negative Breast Neoplasms

Other Information

ATC CodeN/A